Drugs for Neglected Diseases initiative (DNDi)
DNDi is a
nonprofit drug research and development organization that is
developing new treatments for neglected diseases. Our partnership
supplies thousands of our compounds to be screened for activity
against leishmania, Chagas disease and helminth infections. Our
relationship expanded in 2012 to include a four-year joint research
and nonexclusive licensing agreement. This provides DNDi access to
selected classes of AbbVie’s proprietary molecules, identified from
the above screens, and accompanying data to guide the search for
improved treatments. Any products developed as a result of this
partnership are provided to endemic countries by DNDi at the lowest
sustainable price to ensure the greatest patient access
Gates Foundation TB Drug Accelerator (TBDA) consortium
As a founding member of TBDA, AbbVie has provided over 100,000 of
our compounds for screening against replicating tuberculosis (TB).
Active compounds from these screens are shared within the consortium
to speed the identification of the most promising approaches to
shorten and improve the quality of TB therapy. Our scientists are very
engaged with this partnership, providing cheminformatics support and
characterizing lead compounds from other TBDA partners in addition to
the above screening activities.
AbbVie scientists provide technical consulting through the TB Alliance
Scientific Advisory Council, while new compounds are synthesized
at AbbVie and then screened against both replicating and latent TB at
the University of Illinois, Chicago.
Medicines for Malaria Venture (MMV)
AbbVie is working closely with MMV to support two preclinical development
programs of novel antimalarials.
We work with leading research institutions, including Liverpool
School of Tropical Medicine (Anti-Wolbachia Consortium),
University of Washington, University of Sussex and University of
Dundee (Drug Discovery Unit) on NTD screening and research. In
addition, we provide laboratory facilities and mentor student interns
under a program sponsored by Franciscan University of Steubenville
(Franciscan Institute for World Health).
Through our sponsorship of the Brazilian Scientific Mobility
program, AbbVie employees mentor students, sharing their expertise
with the next generation of innovators. The program grants Brazilian
students opportunities to study STEM fields in the United States and
promotes knowledge sharing and capacity building by investing in
future leaders.In Argentina, AbbVie has partnered with the Ministry of
Health of Jujuy since 2012.
AbbVie Foundation treating NTDs
The AbbVie Foundation, a nonprofit charitable organization, supports
advancing progress against NTDs. Its grants support organizations
including the University of Notre Dame and MAP International, helps
prevent and treat NTDs in Bolivia, the Ivory Coast and Haiti. In the
Ivory Coast, a three-year partnership with MAP International is
helping to treat Buruli ulcer (a severe skin ulceration) through
education campaigns, health care professional training and treatment.